Printable version (PDF) 

GAS

See OIL AND GAS

GENERIC DRUGS

– Alzheimer's drug, declaratory judgment noninfringement suit upheld despite withdrawn claims, alternative methods of marketing generic version unavailable (Fed. Cir.), 80:776
– Antitrust, delay of marketplace introduction

– – Cipro

– – – Cal. suit challenging “pay-for-delay” settlement dismissed, appeal filed (Cal. Ct. App.), 80:131
– – – Reverse payment agreement by maker to delay generic version not antitrust violation (2d Cir.), 80:6; (rehear en banc sought), 80:124; court issues correction, 80:358; (en banc rehear den), 80:636; (U.S., rev sought), 81:299

– – EU antitrust regulator

– – – Decline in pay-for-delay patent settlements found, 80:353
– – – Investigators seek information from firms, 81:351

– – FTC seeks to end circuit split, 80:788
– – Hill Watch, status of bills to ban pay-for-delay settlements, 80:614
– – Legislation to ban pay-for-delay settlements

See LEGISLATION, FEDERAL, HR 4899, S *27, S 3677

– Biologic drugs

– – FDA approval process under Biosimilar Act, BNA Insights, 80:174
– – Process/platform patents, scope of protection, 80:758

– Blood-thinning drugs, preliminary injunction against FDA approval of generic version (D.D.C.), 80:606
– Developing countries, access under WTO agreement, 81:26
– Diabetes drugs, Orange Book listings, generic maker cannot use Hatch-Waxman counterclaim to challenge overbroad use code (Fed. Cir., rehear en banc den), 80:474; (U.S., rev sought), 81:314
– False advertising, labeling of nutritional supplement (S.D.N.Y.), 81:221
– Hatch-Waxman Act, preparation for litigation, BNA Insights, 81:36
– Hypertension drug patent valid, generic equivalent infringing (Fed. Cir.), 80:648; (U.S., rev sought), 81:299
– Legislative activity table, May 21, 80:106; June 4, 80:170; July 23, 80:390; Aug. 20, 80:547; Nov. 19, 81:93; Nov. 26, 81:121; Dec. 17, 81:233
– Mucinex brand expectorant, doctrine of equivalents infringement (Fed. Cir.), 80:504
– Osteoporosis drug patents not invalid for obviousness (Fed. Cir.), 80:637
– Premature expiration of patent, generic exclusivity period not terminated (U.S., rev sought), 80:829; (rev den), 81:344
– Respiratory drug marketed with FDA-required label, inducement of patent infringement (Fed. Cir.), 81:17
– Seizure by EU of alleged patent-infringing products, India and Brazil seek WTO dispute proceedings, 80:64; India and EU near resolution of dispute, 80:845
– Temodar cancer drug patent enforceable (Fed. Cir.), 81:77

GOVERNMENT OPERATIONS

– Defense Dept., update of IP text in acquisition regulations, 80:738

Contact the Webmaster at webmaster@bna.com
1801 S. Bell Street, Arlington, VA 22202 - Phone: 1-800-372-1033

Copyright © The Bureau of National Affairs, Inc. All Rights Reserved.